Deloitte Finds Generative AI Revolutionizing Dealmaking Trends
While investment will continue to grow so will the expectation of tangible, near-term results.
In a recent study, Deloitte announced insightful findings from its inaugural survey on Generative AI (GenAI) within the realm of mergers and acquisitions (M&A). The survey garnered responses from 1,000 leaders in corporate and private equity (PE) sectors across major industries in the U.S. It highlights the evolving landscape of dealmaking spurred by the integration of GenAI technologies.
Key Insights from the Survey
According to Erik Dilger, managing director at Deloitte Financial Advisory Services LLP, the 2025 survey illustrates that dealmakers are progressively confident in GenAI’s potential to transform the M&A landscape. Organizations are adapting their strategies to seize the significant benefits that GenAI can provide during the deal lifecycle. Although many companies are still in the nascent stages of adopting this technology, they are keenly focused on exploring its potential in enhancing decision-making, finding new sources of value, and realizing post-deal synergies.
Rapid Integration of GenAI
The survey results convey that a striking 86% of responding companies have begun integrating GenAI into their M&A workflows, with a noteworthy 65% having made such advancements in the past year alone. This rapid adoption indicates an acknowledgment of GenAI's capabilities to reshape traditional dealmaking practices, marking a significant shift in how businesses approach transactions.
Investment Trends Reflect Growing Confidence
The results also reveal a robust inclination to invest in GenAI technologies. Among the organizations surveyed, 83% indicated they had allocated over $1 million towards the technology, specifically benefiting their M&A teams. The enthusiasm is palpable, as many predict enhancements in their GenAI investments over the ????????? 12 months; some anticipate slight increases, while others foresee significant boosts.
Expectation of Returns on Investments
As firms embrace GenAI, there is an increased focus on the anticipated returns on investments (ROI). A substantial majority of organizations expect quantifiable benefits from their GenAI initiatives within one to three years. In fact, 81% of participating private equity firms share this optimistic outlook, alongside 80% of corporate respondents, which reflects a strategic pivot toward initiatives promising measurable impacts.
Impact Across the Deal Cycle
Generative AI is poised to influence every aspect of the deal cycle, although the most considerable traction appears in the initial phases. Specifically, 40% of GenAI adopters utilize the technology for M&A strategy and market assessments, with 35% applying it to target identification and screening, as well as due diligence.
Cautious Adoption Amid Concerns
Despite the enthusiastic embrace of GenAI, concerns remain. A significant 67% of survey respondents cited data security as a paramount issue, underscoring the need to address challenges related to data quality and availability, identified by 65% of participants. This cautious approach reflects a balance between innovation and risk management as organizations navigate the integration of GenAI technologies.
Conclusion
Deloitte's inaugural GenAI in M&A survey illustrates a crucial turning point in dealmaking practices. As organizations strive to integrate innovative technologies, GenAI is expected to play a vital role in reshaping the future of M&A transactions. By fostering a culture of adaptability and prioritizing tangible returns on investment, leaders in finance stand to benefit significantly as they embrace this transformative potential.
Frequently Asked Questions
What is Generative AI's role in dealmaking?
Generative AI is transforming dealmaking by enhancing decision-making, identifying new value sources, and streamlining post-deal integrations.
How many companies are integrating Generative AI?
According to the survey, 86% of organizations have integrated GenAI into their M&A workflows.
What percentage of firms expect a return on their GenAI investments?
Approximately 81% of private equity firms and 80% of corporate entities expect measurable returns from their GenAI investments within one to three years.
What are the primary concerns regarding GenAI adoption?
Data security is a significant concern noted by 67% of respondents, along with issues related to data quality and availability.
How is GenAI affecting pre-sign activities in M&A?
GenAI is significantly utilized in pre-sign activities, including M&A strategy, target identification, and due diligence processes.
